Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy Joanna Zurko, MD, Amitkumar Mehta, MD Mayo Clinic Proceedings: Innovations, Quality & Outcomes Volume 2, Issue 1, Pages 74-77 (March 2018) DOI: 10.1016/j.mayocpiqo.2017.12.001 Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 1 Axial T2 FLAIR MRI of patient on day 6 of hospitalization and day 4 of dexamethasone therapy. FLAIR = fluid-attenuated inversion recovery; MRI = magnetic resonance imaging. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 2018 2, 74-77DOI: (10.1016/j.mayocpiqo.2017.12.001) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 2 Axial T2 FLAIR MRI of patient 6 weeks after presentation, 2 weeks after completion of dexamethasone therapy. FLAIR = fluid-attenuated inversion recovery; MRI = magnetic resonance imaging. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 2018 2, 74-77DOI: (10.1016/j.mayocpiqo.2017.12.001) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions